+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 70Years
All Genders
ID07551037

Study of Personalized Peptide Vaccine Immunotherapy for Maintenance Treatment in Adults with Acute Myeloid Leukemia

Led by Fujian Medical University Union Hospital · Updated on 2026-05-01

90

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Acute myeloid leukemia AML is a common adult leukemia with high recurrence rates after standard chemotherapy, and less than 40% long-term survival. This trial focuses on a new personalized immunotherapy approach using vaccines made from a patients own AML cells to prevent relapse. The study compares this vaccine given during versus after consolidation chemotherapy, aiming to find the best timing and establish safe, effective maintenance therapy for AML patients. Participants receive one of three treatments routine consolidation chemotherapy alone, immunotherapy combined with consolidation chemotherapy, or immunotherapy after completing consolidation chemotherapy. The personalized vaccine is prepared using a patented method to cover all tumor antigens and delivered by intradermal injection. The study uses a randomized controlled design to evaluate these approaches. During the study, participants undergo regular assessments including overall survival and remission rates at various time points up to one year. Researchers monitor immune responses, disease progression, and safety. The trial lasts through consolidation and maintenance phases, with follow-up to evaluate long-term outcomes and treatment effects on AML recurrence and survival.

CONDITIONS

Brief Title

Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy

Research Team

M

Meijuan Huang

S

Shuxia Zhang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here